NCT01760291

Continued Access to PREVAIL (CAP2) - WATCHMAN Left Atrial Appendage (LAA) Closure Technology

Continued Access to PREVAIL (CAP2)- WATCHMAN Left Atrial Appendage (LAA) Closure Technology

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 576 (actual)
• Sponsor: Boston Scientific Corporation · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

To provide additional information about the safety and efficacy of the WATCHMAN LAA Closure Technology

Detailed description

This Continued Access Protocol is a prospective, non-randomized, multicenter study to allow continued access to the WATCHMAN LAA Closure Technology during the data analysis, reporting and review of the PREVAIL pivotal study Pre-Market Application by FDA.

Conditions

• Atrial Fibrillation

Interventions

Type	Name	Description
DEVICE	WATCHMAN LAA Closure Technology

Timeline

• Start date: 2012-09-01
• Primary completion: 2019-04-01
• Completion: 2019-04-01
• First posted: 2013-01-04
• Last updated: 2022-03-29
• Results posted: 2021-11-24

Locations

3 sites across 1 country: United States